Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. Th…


Good News for Galapagos

It has been a huge month for Galapagos, with press releases issued in rapid succession. The news is all positive; the company has, in a very short…

POPULAR TAGS

Argenx raised over $300 million in their US public offering

Written by ALB on in the category news with the tags , .


18 September 2018 - Read the press release here.

Argenx is a Belgian clinical-stage biotechnology company, developing differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. This week they announced the pricing of an underwritten public offering in the United States and an offering in Europe only to qualified investors, with anticipated gross proceeds totalling approximately $300.6 million from the sale of 3,475,000 American Depositary Shares at a price to the public of $86.50 per ADS.

The public offering comes shortly after the company announced positive Phase II results for its lead autoimmune drug candidate, efgartigimod. Argenx now plans to progress efgartigimod, an antibody fragment inspired by llama antibodies, to Phase III trials for treatment of the autoimmune blood disease primary immune thrombocytopenia (ITP).

Read more about: , .

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. Th…


Good News for Galapagos

It has been a huge month for Galapagos, with press releases issued in rapid succession. The news is all positive; the company has, in a very short…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation KU Leuven Janssen Itera Life Science Biowin UGent GSK Flanders.bio V-Bio Ventures Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.